Latest news

Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner? Explicyte is planning a new in vivo shuttle session by mid March, to be held on a series of either subcutaneously- or orthotopically-inoculated syngeneic tumor mouse models.

We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We are glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.

Explicyte is planning a new in vivo shuttle session by mid-November that can be held on a series of syngeneic tumor mouse models. This shuttle session can focus either on only an in vivo efficacy monitoring or on a comprehensive assessment relying on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.